3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
88
Breast Neoplasms
49
Prostatic Neoplasms
43
Squamous Cell Carcinoma of Head and Neck
34
Lung Neoplasms
24
Stomach Neoplasms
19
Neoplasms
19
Neoplasm Metastasis
17
Head and Neck Neoplasms
17
Parkinson Disease 4, Autosomal Dominant Lewy Body
14
Urinary Bladder Neoplasms
13
Carcinoma, Transitional Cell
11
Triple Negative Breast Neoplasms
10
Ovarian Neoplasms
8
Endometrial Neoplasms
8
Carcinoma, Squamous Cell
8
Adenocarcinoma
8
Non-Muscle Invasive Bladder Neoplasms
7
HER2-positive Breast Cancer
7
Prostatic Neoplasms, Castration-Resistant
6
Melanoma
6
Carcinoma
6
Small Cell Lung Carcinoma
5
Nasopharyngeal Carcinoma
5
Esophageal Squamous Cell Carcinoma
5
Esophageal Neoplasms
5
Advanced Solid Tumors
5
Uterine Cervical Neoplasms
4
Sarcoma
4
Oropharyngeal Neoplasms
4
Interventions
tremelimumab
4
Ipilimumab
4
lenvatinib
3
durvalumab
3
Nivolumab
3
pembrolizumab
2
balstilimab
2
Pemetrexed
2
Carboplatin
2
Bevacizumab
2
spartalizumab
1
relatlimab
1
poly ICLC
1
osimertinib
1
cemiplimab
1
Vemurafenib
1
Vascular Endothelial Growth Factor A
1
Standard of Care
1
Platinum
1
Peptides
1
Paclitaxel
1
Opdualag
1
Docetaxel
1
Capecitabine
1
Blood Specimen Collection
1
Axitinib
1
Antibodies, Bispecific
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Diabetes Mellitus, Insulin-Dependent, 12
×
Docetaxel
×
1 year
×
Clear all
NCT05142189
2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1
Recruiting
320 enrolled